Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a dozen children with a rare, genetic form of deafness.

BioCryst goes ‘all in’ on rare swelling disease with Astria deal

A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema that complements its daily pill.

Pharma’s real-world data dilemma: Strategic asset or wasted resource?

A young biotech nets $70M for a new type of allergy drug

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company says could lead to faster and more complete disease control.

J&J plans to spin out orthopedics business

CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such as cardiovascular and robotics.

AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, issues at a Novo plant are impacting multiple drugmakers and an investor wants Novavax to sell itself.